Skip to main content

Treatment-resistant depression: molecular mechanisms and management.

Publication ,  Journal Article
Kajumba, MM; Kakooza-Mwesige, A; Nakasujja, N; Koltai, D; Canli, T
Published in: Mol Biomed
October 17, 2024

Due to the heterogeneous nature of depression, the underlying etiological mechanisms greatly differ among individuals, and there are no known subtype-specific biomarkers to serve as precise targets for therapeutic efficacy. The extensive research efforts over the past decades have not yielded much success, and the currently used first-line conventional antidepressants are still ineffective for close to 66% of patients. Most clinicians use trial-and-error treatment approaches, which seem beneficial to only a fraction of patients, with some eventually developing treatment resistance. Here, we review evidence from both preclinical and clinical studies on the pathogenesis of depression and antidepressant treatment response. We also discuss the efficacy of the currently used pharmacological and non-pharmacological approaches, as well as the novel emerging therapies. The review reveals that the underlying mechanisms in the pathogenesis of depression and antidepressant response, are not specific, but rather involve an interplay between various neurotransmitter systems, inflammatory mediators, stress, HPA axis dysregulation, genetics, and other psycho-neurophysiological factors. None of the current depression hypotheses sufficiently accounts for the interactional mechanisms involved in both its etiology and treatment response, which could partly explain the limited success in discovering efficacious antidepressant treatment. Effective management of treatment-resistant depression (TRD) requires targeting several interactional mechanisms, using subtype-specific and/or personalized therapeutic modalities, which could, for example, include multi-target pharmacotherapies in augmentation with psychotherapy and/or other non-pharmacological approaches. Future research guided by interaction mechanisms hypotheses could provide more insights into potential etiologies of TRD, precision biomarker targets, and efficacious therapeutic modalities.

Duke Scholars

Published In

Mol Biomed

DOI

EISSN

2662-8651

Publication Date

October 17, 2024

Volume

5

Issue

1

Start / End Page

43

Location

Singapore

Related Subject Headings

  • Humans
  • Depressive Disorder, Treatment-Resistant
  • Antidepressive Agents
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kajumba, M. M., Kakooza-Mwesige, A., Nakasujja, N., Koltai, D., & Canli, T. (2024). Treatment-resistant depression: molecular mechanisms and management. Mol Biomed, 5(1), 43. https://doi.org/10.1186/s43556-024-00205-y
Kajumba, Mayanja M., Angelina Kakooza-Mwesige, Noeline Nakasujja, Deborah Koltai, and Turhan Canli. “Treatment-resistant depression: molecular mechanisms and management.Mol Biomed 5, no. 1 (October 17, 2024): 43. https://doi.org/10.1186/s43556-024-00205-y.
Kajumba MM, Kakooza-Mwesige A, Nakasujja N, Koltai D, Canli T. Treatment-resistant depression: molecular mechanisms and management. Mol Biomed. 2024 Oct 17;5(1):43.
Kajumba, Mayanja M., et al. “Treatment-resistant depression: molecular mechanisms and management.Mol Biomed, vol. 5, no. 1, Oct. 2024, p. 43. Pubmed, doi:10.1186/s43556-024-00205-y.
Kajumba MM, Kakooza-Mwesige A, Nakasujja N, Koltai D, Canli T. Treatment-resistant depression: molecular mechanisms and management. Mol Biomed. 2024 Oct 17;5(1):43.

Published In

Mol Biomed

DOI

EISSN

2662-8651

Publication Date

October 17, 2024

Volume

5

Issue

1

Start / End Page

43

Location

Singapore

Related Subject Headings

  • Humans
  • Depressive Disorder, Treatment-Resistant
  • Antidepressive Agents
  • Animals